Mar. 16 at 7:07 PM
$XERS These psychological games are simply a testament to Xeris' gems.
When you have a rapidly growing drug with blockbuster potential, it's almost inevitable that hyenas will come knocking. Fortunately, Recorlev patents are well protected in the Orange Book till 2040. Therefore, it's either nothing, or, in the worst case, throwing them a bone.
This is also the best buying opportunity for those who are not yet well positioned, or want to buy-in for dirt cheap.
No one in their right mind will be willing to sell Xeris shares for even double the current price once the company likely reaches around
$400M in revenue by the end of the year, with 87% gross margins, improving QoQ EBITDA, and 2-3 Blockbuster potential drug (XP-8121) already in Phase 3 with high commercial probability, joining Recorlev and the other proprietary products.
You rarely see such a combination at this stage for less than a
$3B market cap, if not closer to
$5B.
